Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | BRAF | P15056 | 2/20 | 0.68 |
| ▸ | MET | P08581 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515372 | 0.87 | KDR (0.80) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL2517139 | 0.87 | KDR (0.71) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL12205926 | 0.86 | KDR (1.00) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL4283995 | 0.85 | KDR (0.71) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL2521217 | 0.85 | KDR (0.75) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL4280407 | 0.85 | KDR (0.69) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL12231750 | 0.85 | KDR (0.80) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL14292437 | 0.84 | KDR (0.89) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL2514289 | 0.84 | KDR (0.79) | KDRAURKAPDGFRBKITFLT1 | |
| SCHEMBL2513594 | 0.84 | KDR (1.00) | KDRAURKAPDGFRBKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273741-B2 | Imidazo-pyridazinyl compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044049-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034812-B2 | Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDR 1/4885AURKA 370/4885PDGFRB 7/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDR 1/4885AURKA 370/4885PDGFRB 7/4885 |
| US-20090306374-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDR 1/4885AURKA 370/4885PDGFRB 7/4885 |
| US-20100168424-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | KDR 1/4885AURKA 350/4885PDGFRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.